A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Clinical trial NCT03508700 · COMPLETED
Trial details
- NCT number
- NCT03508700
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-19
- Primary completion
- 2019-09-30
- Enrollment
- 93
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.